查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1705500

2025年全球癌症伴同性診斷市場報告

Oncology Companion Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年癌症伴同性診斷的市場規模將快速成長。到2029年，這一數字將成長至62.1億美元，年複合成長率（CAGR）為13.0%。預測期內的成長可以歸因於個人化醫療日益成長的重要性、診斷測試的增加、對個人化癌症治療的日益關注、醫療保健支出的增加以及癌症發病率和認知的提高。預測期內的關鍵趨勢包括診斷技術的進步、次世代定序(NGS)、人工智慧 (AI) 的整合、液態切片技術、照護現場診斷伴同性的開發以及創新測試技術。

預計未來幾年癌症盛行率的上升將推動癌症伴同性診斷市場的成長。癌症是一組複雜的疾病，其特徵是細胞異常生長並不受控制地擴散。癌症病例的增加可歸因於生活方式的改變、環境影響、肥胖症流行、吸煙和遺傳傾向等因素。癌症伴同性診斷在精準醫療中發揮關鍵作用，並將透過實現個人化治療方法選擇、改善治療結果、減少副作用、促進臨床試驗登記和加強治療監測來改變癌症治療。例如，美國政府機構國家癌症研究所在2024年5月報告稱，2022年每年將有約2,000萬例新發癌症病例和970萬例癌症相關死亡病例。到2040年，預計每年新發癌症病例數將增加至2,990萬例，癌症相關死亡人數將達1,530萬例。因此，癌症發生率的上升推動了癌症伴同性診斷市場的成長。

為了保持競爭力，癌症伴同性診斷市場的主要企業正專注於開發創新產品，尤其是體外診斷藥物。體外診斷測試是在受控的實驗室環境中對從患者體外採集的樣本進行的，可以提供有關腫瘤生物學的重要見解，指南治療決策。例如，著名生物技術公司 Illumina 於 2022 年 5 月為其 TruSight Oncology (TSO) Comprehensive (EU) 檢測引入了泛癌症伴同性診斷 (CDx) 適應症。此診斷檢測透過評估多種腫瘤基因和生物標記提供全面的腫瘤概況，使醫療保健提供者能夠為患有一系列固態惡性腫瘤的患者量身定做標靶治療。透過評估腫瘤突變負擔（TMB）和微衛星不穩定性（MSI）狀態等關鍵參數，該測試提高了治療的精確度和有效性。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、感染疾病、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球癌症伴同性診斷PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球癌症伴同性診斷市場：成長率分析
  • 全球癌症伴同性診斷市場表現：規模與成長，2019-2024
  • 全球癌症伴同性診斷市場預測：規模與成長，2024-2029 年，2034 年
  • 全球癌症伴同性診斷總目標市場（TAM）

第6章市場區隔

  • 全球癌症伴同性診斷市場：依產品、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 裝置
  • 耗材
  • 軟體
  • 全球癌症伴同性診斷市場：按疾病類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 黑色素瘤
  • 乳癌
  • 大腸直腸癌
  • 白血病
  • 攝護腺癌
  • 其他類型的疾病
  • 全球癌症伴同性診斷市場（依技術、績效及預測），2019-2024 年、2024-2029 年及 2034 年
  • 免疫組織化學（IHC）
  • 原位雜合技術（ISH）或螢光原位雜合技術（FISH）
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 其他技術
  • 全球癌症伴同性診斷市場（按最終用戶、績效及預測），2019-2024 年、2024-2029 年及 2034 年
  • 醫院
  • 病理或診斷實驗室
  • 學術醫療中心
  • 其他最終用戶
  • 全球癌症伴同性診斷市場，儀器細分，按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素鏈鎖反應（PCR）設備
  • 次世代定序（NGS）系統
  • 免疫組織化學（IHC）設備
  • 螢光原位雜合反應（FISH）設備
  • 微陣列平台
  • 全球癌症伴同性診斷市場依耗材類型、績效及預測細分，2019-2024 年、2024-2029 年、2034 年
  • 試劑及套件（DNA或RNA萃取套件、PCR試劑）
  • 切片穿刺針
  • 滑動和傾斜測試
  • 控制和校準樣品
  • 全球癌症伴同性診斷市場軟體細分（按類型、效能和預測），2019-2024 年、2024-2029 年、2034 年
  • 資料分析軟體
  • 生物資訊軟體（用於基因表現分析）
  • 伴同性診斷決策支援軟體
  • 臨床工作流程管理軟體

第7章 區域和國家分析

  • 全球癌症伴同性診斷市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症伴同性診斷市場（按國家/地區分類）、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 癌症伴同性診斷市場：競爭格局
  • 癌症伴同性診斷市場：公司簡介
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Laboratory Corporation of America Holdings（LabCorp）
  • Quest Diagnostics Incorporated
  • Eurofins Scientific SE
  • Agilent Technologies Inc.
  • Illumina Inc.
  • PerkinElmer Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Exact Sciences Corporation
  • BGI Genomics Co. Ltd.
  • Natera Inc.
  • Myriad Genetics Inc.
  • ARUP Laboratories

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年癌症伴同性診斷市場：提供新機會的國家
  • 2029年癌症伴同性診斷市場：細分領域帶來新機會
  • 2029年癌症伴同性診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r30813

Oncology companion diagnostics are medical tests designed to identify specific biomarkers, indicating which patients are most likely to respond favorably to a particular cancer treatment. These diagnostics play a crucial role in the development and application of targeted therapies, ensuring that treatments are customized to match the unique characteristics of a patient's tumor. By providing insights into the molecular and genetic profile of cancer, companion diagnostics enable more personalized and efficient treatment strategies, leading to improved outcomes and reduced adverse effects.

The primary products within the oncology companion diagnostics market include instruments, consumables, and software. Instruments encompass a diverse array of tools and devices utilized for various purposes across different fields. These diagnostics cater to a range of disease types such as melanoma, breast cancer, colorectal cancer, leukemia, prostate cancer, among others. They leverage various technologies including immunohistochemistry (IHC), in situ hybridization (ISH) or fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. End users of oncology companion diagnostics include hospitals, pathology or diagnostic laboratories, academic medical centers, and others.

The oncology companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology companion diagnostics market statistics, including oncology companion diagnostics industry global market size, regional shares, competitors with an oncology companion diagnostics market share, detailed oncology companion diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the oncology companion diagnostics industry. This oncology companion diagnostics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology companion diagnostics market size has grown rapidly in recent years. It will grow from $3.35 billion in 2024 to $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, the increasing global incidence of cancer, the growing need for targeted therapy, and the growing number of clinical trials.

The oncology companion diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.

The increasing prevalence of cancer is expected to drive the growth of the oncology companion diagnostics market in the future. Cancer is a complex group of diseases characterized by abnormal cell growth that spreads uncontrollably. The rise in cancer cases can be attributed to factors such as lifestyle changes, environmental influences, the obesity epidemic, tobacco use, and genetic predispositions. Oncology companion diagnostics play a critical role in precision medicine, transforming cancer care by enabling personalized treatment selection, improving treatment effectiveness, reducing side effects, facilitating clinical trial participation, and enhancing treatment monitoring. For example, the National Cancer Institute, a US-based government agency, reported in May 2024 that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred annually in 2022. By 2040, predictions suggest that the number of new cancer cases will rise to 29.9 million, with 15.3 million cancer-related deaths annually. As a result, the increasing cancer incidence is driving the growth of the oncology companion diagnostics market.

Leading companies in the oncology companion diagnostics market are concentrating their efforts on developing innovative products, particularly in vitro diagnostic tests, to maintain their competitive edge. In vitro diagnostic tests, conducted on samples obtained from patients outside of the body in controlled laboratory environments, provide critical insights into tumor biology and guide treatment decision-making. For example, Illumina Inc., a prominent biotechnology company, introduced a pan-cancer companion diagnostic (CDx) indication for its TruSight Oncology (TSO) Comprehensive (EU) test in May 2022. This diagnostic assay offers a comprehensive tumor profile by evaluating multiple tumor genes and biomarkers, empowering healthcare providers to tailor targeted therapy for patients with various solid malignant neoplasms. By assessing essential parameters such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, this test enhances treatment precision and effectiveness.

In January 2024, Agilent Technologies Inc., a US-based diagnostics company, entered into a partnership with Incyte Corporation for an undisclosed amount. This collaboration aims to strengthen Agilent's companion diagnostics portfolio and support Incyte's hematology and oncology treatments through advanced, precision diagnostics. Incyte Corporation, a US-based pharmaceutical company, specializes in the development and commercialization of oncology medications.

Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology companion diagnostics market consists of revenues earned by entities by providing services such as biomarker testing, patient stratification, monitoring treatment response, predicting drug resistance, clinical trial enrollment, comprehensive genomic testing, therapy resistance testing, hereditary cancer testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology companion diagnostics market also includes sales of polymerase chain reaction instruments, immunohistochemistry (IHC) staining kits, companion diagnostic test kits, liquid biopsy platforms, gene expression profiling kits, mass spectrometry systems, flow cytometry analyzers, tissue microarray instruments, and electrochemical biosensors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instrument; Consumables; Software
  • 2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
  • 3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
  • 4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
  • Subsegments:
  • 1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
  • 2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
  • 3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
  • Companies Mentioned: F. Hoffmann-La Roche AG; Bayer Diagnostic; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Companion Diagnostics Market Characteristics

3. Oncology Companion Diagnostics Market Trends And Strategies

4. Oncology Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oncology Companion Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oncology Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oncology Companion Diagnostics Market Growth Rate Analysis
  • 5.4. Global Oncology Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oncology Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oncology Companion Diagnostics Total Addressable Market (TAM)

6. Oncology Companion Diagnostics Market Segmentation

  • 6.1. Global Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instrument
  • Consumables
  • Software
  • 6.2. Global Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Melanoma
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Prostate Cancer
  • Other Disease Types
  • 6.3. Global Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other Technologies
  • 6.4. Global Oncology Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Pathology Or Diagnostic Laboratory
  • Academic Medical Center
  • Other End-Users
  • 6.5. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Instrument, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR) Instruments
  • Next-Generation Sequencing (NGS) Systems
  • Immunohistochemistry (IHC) Instruments
  • Fluorescence In Situ Hybridization (FISH) Instruments
  • Microarray Platforms
  • 6.6. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents)
  • Biopsy Needles
  • Testing Slides And Chips
  • Control And Calibration Samples
  • 6.7. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Bioinformatics Software (For Gene Expression Analysis)
  • Companion Diagnostic Decision Support Software
  • Clinical Workflow Management Software

7. Oncology Companion Diagnostics Market Regional And Country Analysis

  • 7.1. Global Oncology Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oncology Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Companion Diagnostics Market

  • 8.1. Asia-Pacific Oncology Companion Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Companion Diagnostics Market

  • 9.1. China Oncology Companion Diagnostics Market Overview
  • 9.2. China Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Companion Diagnostics Market

  • 10.1. India Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Companion Diagnostics Market

  • 11.1. Japan Oncology Companion Diagnostics Market Overview
  • 11.2. Japan Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Companion Diagnostics Market

  • 12.1. Australia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Companion Diagnostics Market

  • 13.1. Indonesia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Companion Diagnostics Market

  • 14.1. South Korea Oncology Companion Diagnostics Market Overview
  • 14.2. South Korea Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Companion Diagnostics Market

  • 15.1. Western Europe Oncology Companion Diagnostics Market Overview
  • 15.2. Western Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Companion Diagnostics Market

  • 16.1. UK Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Companion Diagnostics Market

  • 17.1. Germany Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Companion Diagnostics Market

  • 18.1. France Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Companion Diagnostics Market

  • 19.1. Italy Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Companion Diagnostics Market

  • 20.1. Spain Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Companion Diagnostics Market

  • 21.1. Eastern Europe Oncology Companion Diagnostics Market Overview
  • 21.2. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Companion Diagnostics Market

  • 22.1. Russia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Companion Diagnostics Market

  • 23.1. North America Oncology Companion Diagnostics Market Overview
  • 23.2. North America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Companion Diagnostics Market

  • 24.1. USA Oncology Companion Diagnostics Market Overview
  • 24.2. USA Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Companion Diagnostics Market

  • 25.1. Canada Oncology Companion Diagnostics Market Overview
  • 25.2. Canada Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Companion Diagnostics Market

  • 26.1. South America Oncology Companion Diagnostics Market Overview
  • 26.2. South America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Companion Diagnostics Market

  • 27.1. Brazil Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Companion Diagnostics Market

  • 28.1. Middle East Oncology Companion Diagnostics Market Overview
  • 28.2. Middle East Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Companion Diagnostics Market

  • 29.1. Africa Oncology Companion Diagnostics Market Overview
  • 29.2. Africa Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Companion Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Oncology Companion Diagnostics Market Competitive Landscape
  • 30.2. Oncology Companion Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Companion Diagnostics Market Other Major And Innovative Companies

  • 31.1. Laboratory Corporation of America Holdings (LabCorp)
  • 31.2. Quest Diagnostics Incorporated
  • 31.3. Eurofins Scientific SE
  • 31.4. Agilent Technologies Inc.
  • 31.5. Illumina Inc.
  • 31.6. PerkinElmer Inc.
  • 31.7. bioMerieux SA
  • 31.8. Sysmex Corporation
  • 31.9. Bio-Rad Laboratories Inc.
  • 31.10. QIAGEN N.V.
  • 31.11. Exact Sciences Corporation
  • 31.12. BGI Genomics Co. Ltd.
  • 31.13. Natera Inc.
  • 31.14. Myriad Genetics Inc.
  • 31.15. ARUP Laboratories

32. Global Oncology Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Companion Diagnostics Market

34. Recent Developments In The Oncology Companion Diagnostics Market

35. Oncology Companion Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Oncology Companion Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oncology Companion Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oncology Companion Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer